When to Begin Highly Active Antiretroviral Therapy? Evidence Supporting Initiation of Therapy at CD4+ Lymphocyte Counts <350 cells/ L
Open Access
- 1 October 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (7) , 951-958
- https://doi.org/10.1086/377606
Abstract
We assessed the risk of acquired immunodeficiency syndrome (AIDS)-related opportunistic illness or death among persons first prescribed highly activeKeywords
This publication has 24 references indexed in Scilit:
- Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug TherapyJAMA, 2001
- HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral LoadJAMA, 2001
- HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapyAIDS, 2001
- The Case for More Cautious, Patient-Focused Antiretroviral TherapyAnnals of Internal Medicine, 2000
- AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral TherapyJAMA, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Caution: should we be treating HIV infection early?The Lancet, 1998
- The case for conservative management of early HIV disease.JAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Antiretroviral Therapy for HIV Infection in 1996JAMA, 1996